Clinical Trials Logo

Clinical Trial Summary

Edoxaban (also referred to as Lixiana) is an anti-clotting drug, approved by Health Canada for the prevention of stroke in patients with atrial fibrillation (abnormal heart rhythm). This study is being done to try to determine the best time to start apixaban treatment after an ischemic stroke has occurred.

The purpose of the LASER study is to determine the safety of early edoxaban use after TIA/ischemic stroke in patients with atrial fibrillation using advanced MR imaging. This study will also gather information about participant general well being, mental status, and the effects of the TIA/stroke on daily living, as well as CT and MRI of the brain.


Clinical Trial Description

The primary aim of the Lixiana Acute Stroke Evaluation Registry is to demonstrate the safety of edoxaban initiation within 5 days of cardioembolic stroke. Safety will be established by demonstrating low rates of hemorrhage in this setting. The secondary aim is to identify clinical, imaging and RNA transcript predictors of hemorrhagic transformation after cardioembolic stroke.

The Investigators hypothesize that initiation of edoxaban within 5 days of stroke/TIA will not be associated with increased symptomatic HT rates, relative to patients in whom anticoagulation is delayed. The Investigators further hypothesize that early edoxaban initiation will be associated with a lower rate of recurrent ischemic stroke than those in whom it is delayed. The Investigators also hypothesize that RNA expressed in leukocytes at time of stroke can stratify risk of HT in patients treated with edoxaban.

The Lixiana Acute Stroke Evaluation Registry (LASER) is a randomized controlled trial with an associated registry. Patients with previously known or newly diagnosed AF and acute ischemic stroke will be screened in the Emergency Departments or stroke units. A total of 150 male and female participants will be recruited. Informed consent will be obtained from the participant or substitute decision maker, in all cases prior to enrolment.

Participants will be randomized (2:1) to early (≤5 days; n=100) or delayed (6-14 days; n=50) edoxaban initiation. In participants randomized to early treatment, edoxaban will be initiated as soon as possible after the baseline MRI (maximum 24 hours). Participants will be treated with edoxaban (60 mg once daily). If the eGFR is ≤50 ml/min kg or body weight ≤60 kg, the edoxaban dose will be reduced to 30 mg once daily.

The primary endpoint is the rate of symptomatic hemorrhagic transformation (HT) defined as a parenchymal haemorrhage >1/3 the volume of the ischemic infarct (ECASS PH2) associated with clinical deterioration (worsening of NIHSS score of 4 or more points) within 30 days of treatment initiation. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03494530
Study type Observational
Source University of Alberta
Contact Ken Butcher, MD, PhD
Phone 780-248-1927
Email ken.butcher@ualberta.ca
Status Not yet recruiting
Phase
Start date October 15, 2018
Completion date December 31, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT03281590 - Stroke and Cerebrovascular Diseases Registry
Recruiting NCT03728738 - Zero Degree Head Positioning in Hyperacute Large Artery Ischemic Stroke Phase 3
Recruiting NCT03396419 - IMPACT- 24col Collateral Blood Flow Assessment Following SPG Stimulation in Acute Ischemic Stroke (ImpACT-24B Sub-Study)
Recruiting NCT02910180 - Genetic, Metabolic, and Growth Factor Repository for Cerebrovascular Disorders N/A
Recruiting NCT03554642 - Walkbot Robotic Training for Improvement in Gait Phase 3
Completed NCT02922452 - A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects Phase 1
Withdrawn NCT01866189 - Identification of Hypoxic Brain Tissues by F-MISO PET in Acute Ischemic Stroke N/A
Recruiting NCT03041753 - Reperfusion Injury After Stroke Study N/A
Completed NCT02549846 - AdminiStration of Statin On Acute Ischemic stRoke patienT Trial Phase 4
Completed NCT02610803 - Paroxysmal Atrial Fibrillation in Patients With Acute Ischemic Stroke N/A
Completed NCT01678534 - Reparative Therapy in Acute Ischemic Stroke With Allogenic Mesenchymal Stem Cells From Adipose Tissue, Safety Assessment, a Randomised, Double Blind Placebo Controlled Single Center Pilot Clinical Trial Phase 2
Completed NCT01968122 - Registry Study of Stenting for Symptomatic Intracranial Artery Stenosis in China N/A
Not yet recruiting NCT01923818 - Treatment of Rivaroxaban Versus Aspirin for Non-disabling Cerebrovascular Events Phase 2/Phase 3
Completed NCT01983644 - RECO Flow Restoration Device Versus Solitaire FR With the Intention for Thrombectomy Study N/A
Suspended NCT01852201 - POSITIVE Stroke Clinical Trial N/A
Completed NCT02924168 - Radial Shock Waves for Functional Disability in Stroke N/A
Completed NCT01949948 - Study of Tenecteplase Versus Alteplase for Thrombolysis (Clot Dissolving) in Acute Ischemic Stroke Phase 3
Completed NCT02184936 - Measuring Collaterals With Multi-phase CT Angiography in Patients With Ischemic Stroke N/A
Recruiting NCT01526824 - Lovaza's Effect on Clopidogrel in a Neuro Population Phase 0
Completed NCT01188824 - The Safety and Efficacy of Cilostazol in Ischemic Stroke Patients With Peripheral Arterial Disease (SPAD Study) Phase 4